Do patients with acute vertebrobasilar occlusion benefit from an aggressive treatment strategy?
von Kummer
Rüdiger
R
Department of Neuroradiology, University of Technology, Dresden, Germany. ruediger.vonkummer@uniklinikum-dresden.de
D000077284:Abciximab; D000368:Aged; D000800:Angioplasty, Balloon / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D018810:Magnetic Resonance Angiography; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage*; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D015607:Stents; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000379:methods; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014715:Vertebrobasilar Insufficiency / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010960:Plasminogen Activators; D000077284:Abciximab